Cardiovascular outcomes of pediatric seroreverters perinatally exposed to HAART: Design of a longitudinal clinical study

Jill E. Lavigne, William T. Shearer, Bruce Thompson, E. John Orav, Thomas J. Starc, Steven D. Colan, Ricardo Pignatelli, Sharon E. O'Brien, Louis Bezold, Phillip LaRusa, Kirk A. Easley, Irene Cheng, Sarah A. Duffy, Steven E Lipshultz

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Seroreverters (uninfected children of HIV-infected mothers) have exhibited left ventricular (LV) dysfunction. Mitochondrial toxicity associated with in utero of postnatal exposure to highly active antiretroviral therapy (HAART) is a possible mechanism. Adult and animal models have demonstrated associations between LV abnormalities, cardiomyopathy, and components of HAART. Yet, outcomes in children are poorly understood. In this study, we explore HAART-associated LV abnormalities in seroreverters exposed to HAART (n = 144) or never exposed (n = 252). Subjects are drawn from the Women and Infants Transmission Study and the Pediatric Pulmonary and Cardiovascular Complications of HIV Study, respectively. Data include (1) echocardiographic studies of LV structure and function and (2) serologic cardiac biomarkers (cardiac troponin, probrain natriuretic peptide, high-sensitivity C reactive protein), both collected during the first month of life, and again at 6, 12, 24, 36, and 48 months postnatally. Planned analyses include several regression models. At this time, we have access to data for all 252 unexposed children, and 53 exposed subjects are enrolled. The cohorts are similar in terms of gender and race and the recruited subjects are representative of all eligible subjects in terms of exposure to HAART. Recruitment will continue into 2006.

Original languageEnglish
Pages (from-to)187-197
Number of pages11
JournalCardiovascular Toxicology
Volume4
Issue number2
DOIs
StatePublished - Oct 14 2004

Fingerprint

Pediatrics
Highly Active Antiretroviral Therapy
Longitudinal Studies
Natriuretic Peptides
Troponin
Biomarkers
C-Reactive Protein
Toxicity
Animals
HIV
Left Ventricular Dysfunction
Cardiomyopathies
Left Ventricular Function
Animal Models
Mothers
Clinical Studies
Lung

Keywords

  • Antiretroviral therapy
  • Cardiovascular
  • Highly active antiretroviral therapy
  • HIV
  • Mitochondria
  • Prophylaxis
  • Seroreverter
  • Study design
  • Toxicity
  • Vertical transmission

ASJC Scopus subject areas

  • Toxicology
  • Cardiology and Cardiovascular Medicine

Cite this

Lavigne, J. E., Shearer, W. T., Thompson, B., Orav, E. J., Starc, T. J., Colan, S. D., ... Lipshultz, S. E. (2004). Cardiovascular outcomes of pediatric seroreverters perinatally exposed to HAART: Design of a longitudinal clinical study. Cardiovascular Toxicology, 4(2), 187-197. https://doi.org/10.1385/CT:4:2:187

Cardiovascular outcomes of pediatric seroreverters perinatally exposed to HAART : Design of a longitudinal clinical study. / Lavigne, Jill E.; Shearer, William T.; Thompson, Bruce; Orav, E. John; Starc, Thomas J.; Colan, Steven D.; Pignatelli, Ricardo; O'Brien, Sharon E.; Bezold, Louis; LaRusa, Phillip; Easley, Kirk A.; Cheng, Irene; Duffy, Sarah A.; Lipshultz, Steven E.

In: Cardiovascular Toxicology, Vol. 4, No. 2, 14.10.2004, p. 187-197.

Research output: Contribution to journalArticle

Lavigne, JE, Shearer, WT, Thompson, B, Orav, EJ, Starc, TJ, Colan, SD, Pignatelli, R, O'Brien, SE, Bezold, L, LaRusa, P, Easley, KA, Cheng, I, Duffy, SA & Lipshultz, SE 2004, 'Cardiovascular outcomes of pediatric seroreverters perinatally exposed to HAART: Design of a longitudinal clinical study', Cardiovascular Toxicology, vol. 4, no. 2, pp. 187-197. https://doi.org/10.1385/CT:4:2:187
Lavigne, Jill E. ; Shearer, William T. ; Thompson, Bruce ; Orav, E. John ; Starc, Thomas J. ; Colan, Steven D. ; Pignatelli, Ricardo ; O'Brien, Sharon E. ; Bezold, Louis ; LaRusa, Phillip ; Easley, Kirk A. ; Cheng, Irene ; Duffy, Sarah A. ; Lipshultz, Steven E. / Cardiovascular outcomes of pediatric seroreverters perinatally exposed to HAART : Design of a longitudinal clinical study. In: Cardiovascular Toxicology. 2004 ; Vol. 4, No. 2. pp. 187-197.
@article{76ee27e849384fbd8ddf77d4bb05075f,
title = "Cardiovascular outcomes of pediatric seroreverters perinatally exposed to HAART: Design of a longitudinal clinical study",
abstract = "Seroreverters (uninfected children of HIV-infected mothers) have exhibited left ventricular (LV) dysfunction. Mitochondrial toxicity associated with in utero of postnatal exposure to highly active antiretroviral therapy (HAART) is a possible mechanism. Adult and animal models have demonstrated associations between LV abnormalities, cardiomyopathy, and components of HAART. Yet, outcomes in children are poorly understood. In this study, we explore HAART-associated LV abnormalities in seroreverters exposed to HAART (n = 144) or never exposed (n = 252). Subjects are drawn from the Women and Infants Transmission Study and the Pediatric Pulmonary and Cardiovascular Complications of HIV Study, respectively. Data include (1) echocardiographic studies of LV structure and function and (2) serologic cardiac biomarkers (cardiac troponin, probrain natriuretic peptide, high-sensitivity C reactive protein), both collected during the first month of life, and again at 6, 12, 24, 36, and 48 months postnatally. Planned analyses include several regression models. At this time, we have access to data for all 252 unexposed children, and 53 exposed subjects are enrolled. The cohorts are similar in terms of gender and race and the recruited subjects are representative of all eligible subjects in terms of exposure to HAART. Recruitment will continue into 2006.",
keywords = "Antiretroviral therapy, Cardiovascular, Highly active antiretroviral therapy, HIV, Mitochondria, Prophylaxis, Seroreverter, Study design, Toxicity, Vertical transmission",
author = "Lavigne, {Jill E.} and Shearer, {William T.} and Bruce Thompson and Orav, {E. John} and Starc, {Thomas J.} and Colan, {Steven D.} and Ricardo Pignatelli and O'Brien, {Sharon E.} and Louis Bezold and Phillip LaRusa and Easley, {Kirk A.} and Irene Cheng and Duffy, {Sarah A.} and Lipshultz, {Steven E}",
year = "2004",
month = "10",
day = "14",
doi = "10.1385/CT:4:2:187",
language = "English",
volume = "4",
pages = "187--197",
journal = "Cardiovascular Toxicology",
issn = "1530-7905",
publisher = "Humana Press",
number = "2",

}

TY - JOUR

T1 - Cardiovascular outcomes of pediatric seroreverters perinatally exposed to HAART

T2 - Design of a longitudinal clinical study

AU - Lavigne, Jill E.

AU - Shearer, William T.

AU - Thompson, Bruce

AU - Orav, E. John

AU - Starc, Thomas J.

AU - Colan, Steven D.

AU - Pignatelli, Ricardo

AU - O'Brien, Sharon E.

AU - Bezold, Louis

AU - LaRusa, Phillip

AU - Easley, Kirk A.

AU - Cheng, Irene

AU - Duffy, Sarah A.

AU - Lipshultz, Steven E

PY - 2004/10/14

Y1 - 2004/10/14

N2 - Seroreverters (uninfected children of HIV-infected mothers) have exhibited left ventricular (LV) dysfunction. Mitochondrial toxicity associated with in utero of postnatal exposure to highly active antiretroviral therapy (HAART) is a possible mechanism. Adult and animal models have demonstrated associations between LV abnormalities, cardiomyopathy, and components of HAART. Yet, outcomes in children are poorly understood. In this study, we explore HAART-associated LV abnormalities in seroreverters exposed to HAART (n = 144) or never exposed (n = 252). Subjects are drawn from the Women and Infants Transmission Study and the Pediatric Pulmonary and Cardiovascular Complications of HIV Study, respectively. Data include (1) echocardiographic studies of LV structure and function and (2) serologic cardiac biomarkers (cardiac troponin, probrain natriuretic peptide, high-sensitivity C reactive protein), both collected during the first month of life, and again at 6, 12, 24, 36, and 48 months postnatally. Planned analyses include several regression models. At this time, we have access to data for all 252 unexposed children, and 53 exposed subjects are enrolled. The cohorts are similar in terms of gender and race and the recruited subjects are representative of all eligible subjects in terms of exposure to HAART. Recruitment will continue into 2006.

AB - Seroreverters (uninfected children of HIV-infected mothers) have exhibited left ventricular (LV) dysfunction. Mitochondrial toxicity associated with in utero of postnatal exposure to highly active antiretroviral therapy (HAART) is a possible mechanism. Adult and animal models have demonstrated associations between LV abnormalities, cardiomyopathy, and components of HAART. Yet, outcomes in children are poorly understood. In this study, we explore HAART-associated LV abnormalities in seroreverters exposed to HAART (n = 144) or never exposed (n = 252). Subjects are drawn from the Women and Infants Transmission Study and the Pediatric Pulmonary and Cardiovascular Complications of HIV Study, respectively. Data include (1) echocardiographic studies of LV structure and function and (2) serologic cardiac biomarkers (cardiac troponin, probrain natriuretic peptide, high-sensitivity C reactive protein), both collected during the first month of life, and again at 6, 12, 24, 36, and 48 months postnatally. Planned analyses include several regression models. At this time, we have access to data for all 252 unexposed children, and 53 exposed subjects are enrolled. The cohorts are similar in terms of gender and race and the recruited subjects are representative of all eligible subjects in terms of exposure to HAART. Recruitment will continue into 2006.

KW - Antiretroviral therapy

KW - Cardiovascular

KW - Highly active antiretroviral therapy

KW - HIV

KW - Mitochondria

KW - Prophylaxis

KW - Seroreverter

KW - Study design

KW - Toxicity

KW - Vertical transmission

UR - http://www.scopus.com/inward/record.url?scp=4744375732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4744375732&partnerID=8YFLogxK

U2 - 10.1385/CT:4:2:187

DO - 10.1385/CT:4:2:187

M3 - Article

C2 - 15371634

AN - SCOPUS:4744375732

VL - 4

SP - 187

EP - 197

JO - Cardiovascular Toxicology

JF - Cardiovascular Toxicology

SN - 1530-7905

IS - 2

ER -